Caplin Point’s Subsidiary Secures USFDA Nod for Seizures Treatment Injection

Caplin Point Laboratories, a prominent pharmaceutical company serving Latin America and Africa, has announced a significant milestone. Its subsidiary, Caplin Steriles, has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam in Sodium Chloride Injection.

A Breakthrough in Seizure Treatment

Levetiracetam in Sodium Chloride Injection is an antiepileptic drug designed as an adjunctive therapy for partial-onset seizures in adults with epilepsy, myoclonic seizures in adults with juvenile myoclonic epilepsy, and primary generalised tonic-clonic seizures in adults with idiopathic generalised epilepsy. The drug is a generic therapeutic equivalent of the Reference Listed Drug (RLD) from HQ Specialty Pharma Corp.

Market Potential and Company Growth

The US market for Levetiracetam in Sodium Chloride Injection was valued at approximately $19 million for the 12-month period ending November 2024, according to IQVIATM (IMS Health). This approval provides Caplin Steriles with an opportunity to capture a share of this market, further strengthening its presence in the US.

Caplin Point Laboratories has consistently showcased innovation and growth, leveraging its state-of-the-art manufacturing facilities to produce a wide range of finished dosage forms. With this latest milestone, the company continues to affirm its commitment to delivering high-quality, affordable healthcare solutions globally.

Caplin Point Laboratries Share Performance

As of January 20, 2025, 10:30 AM, the Caplin Point Laboratories share price is trading at ₹2,194.00 per share with a decline of 0.56% from its previous day’s closing price. Over the last month, the stock has seen a decline of 5.08% and over the last year, it has surged by 45.90%. The stock has a 52-week high and 52-week low of ₹2,641.00 per share and ₹1,225.00 per share, respectively. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.